Notably, the association between chronic coronary syndrome and FABP4 persisted after adjusting for dyslipidemia with statin use, suggesting that low FABP4 levels may still serve as a useful predictor in treated patients. The gene discussed is FABP4; the disease is metabolic syndrome.